Literature DB >> 11604591

Pathogenic mechanisms mediating antiphospholipid syndrome.

P L Meroni1, P Riboldi.   

Abstract

Antiphospholipid antibodies are the marker for antiphospholipid syndrome. There is evidence that these autoantibodies lead to both thrombotic diathesis and obstetrical manifestations. Besides the known interaction with soluble coagulation factors, in vitro and in vivo experimental models and studies in humans recently have shown the ability of antiphospholipid antibodies to modulate functions of cells involved in coagulation homeostasis. These findings support a new hypothesis to explain the paradox of the prolongation of coagulation assays in vitro and the association with thrombophilic diathesis in vivo. Obstetrical manifestations have been linked to a direct antibody effect on the trophoblast leading to defective placentation that is not necessarily associated with thrombotic phenomena. Phospholipid binding proteins such as beta 2 -glycoprotein I appear to behave as a bridge between circulating antiphospholipid antibodies and cellular targets.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11604591     DOI: 10.1097/00002281-200109000-00006

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  18 in total

Review 1.  Infectious origin of the antiphospholipid syndrome.

Authors:  Y Shoenfeld; M Blank; R Cervera; J Font; E Raschi; P-L Meroni
Journal:  Ann Rheum Dis       Date:  2006-01       Impact factor: 19.103

Review 2.  Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases?

Authors:  Pier Luigi Meroni; Cristina Luzzana; Donatella Ventura
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

3.  High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study.

Authors:  Anna Broder; Jonathan N Tobin; Chaim Putterman
Journal:  J Clin Pathol       Date:  2012-03-03       Impact factor: 3.411

4.  Prevalence of antibodies against oxidised LDL in a cohort of 163 patients with positive anti-phospholipid antibodies and recent thrombosis.

Authors:  Henning Locht; Allan Wiik
Journal:  Rheumatol Int       Date:  2005-09-28       Impact factor: 2.631

5.  Clinical and laboratory characteristics of children positive for antiphospholipid antibodies.

Authors:  Paola Giordano; Riccardina Tesse; Giuseppe Lassandro; Deborah Fracchiolla; Prudenza Ranieri; Antonella Lotito; Domenico De Mattia; Giovanni Carlo Del Vecchio
Journal:  Blood Transfus       Date:  2011-12-21       Impact factor: 3.443

6.  IgG and IgM isotypes of anti-cardiolipin and anti-beta2-glycoprotein i antibodies reflect different forms of recent thrombo-embolic events.

Authors:  Henning Locht; Allan Wiik
Journal:  Clin Rheumatol       Date:  2005-09-22       Impact factor: 2.980

7.  Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro.

Authors:  N Di Simone; E Raschi; C Testoni; R Castellani; M D'Asta; T Shi; S A Krilis; A Caruso; P L Meroni
Journal:  Ann Rheum Dis       Date:  2004-07-15       Impact factor: 19.103

8.  High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome.

Authors:  S Cucnik; T Kveder; I Krizaj; B Rozman; B Bozic
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 9.  Novel insights into associations of antibodies against cardiolipin and beta2-glycoprotein I with clinical features of antiphospholipid syndrome.

Authors:  O Shovman; B Gilburd; O Barzilai; P Langevitz; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

Review 10.  Updating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss.

Authors:  Pier Luigi Meroni; Maria Gerosa; Elena Raschi; Silvia Scurati; Claudia Grossi; Maria O Borghi
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.